Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 7/20 | 0.46 |
| ▸ | BCR | P11274 | 7/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4655004 | 0.87 | CTSC (0.52) | CTSCKCNH2SCN5ASCN9AABL1 | |
| SCHEMBL20267818 | 0.80 | CTSC (0.54) | CTSCKCNH2SCN5ASCN9AABL1 | |
| SCHEMBL14800659 | 0.79 | GRM5 (0.46) | SYK | |
| SCHEMBL24866863 | 0.77 | TDO2 (0.53) | CTSCKCNH2SCN5ASCN9AABL1 | |
| SCHEMBL14801200 | 0.76 | HDAC3 (0.53) | KCNH2SCN5ASCN9A | |
| Hydrochloric Acid SCHEMBL14800138 | 0.74 | HDAC3 (0.51) | KCNH2SCN5ASCN9A | |
| SCHEMBL28396861 | 0.74 | NPC1 (0.51) | CTSCKCNH2SCN5ASCN9AABL1 | |
| SCHEMBL14965803 | 0.74 | MEN1 (0.64) | ABL1NPC1RAB9AL3MBTL1 | |
| SCHEMBL3452125 | 0.74 | CHRNA7 (0.59) | CTSCKCNH2SCN5ASCN9ACHRNA7 | |
| SCHEMBL30568377 | 0.73 | SCN9A (0.61) | CTSCKCNH2SCN5ASCN9AABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760843-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-02 | — | — | EP | disclosed |
| US-8841301-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2760843-A2 | SELECTIVE NR2B ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013048949-A2 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079338-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079338-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | CTSC 3798/4885KCNH2 923/4885SCN5A 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.